drugset
drugset / Trial / NCT00772915

Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT00772915 ↗

Phase 2 Completed 39 enrolled Mayo Clinic National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Lenalidomide and dexamethasone may stop the growth of multiple myeloma by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works with or without dexamethasone in treating patients with newly diagnosed multiple myeloma.

Timeline

Start
2008-12-03
Primary completion
2011-03-22
Completion
2018-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 40 mg Oral
Subject Lenalidomide Other / unclassified 25 mg Oral

Indications

plasma cell myeloma